| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Harry Karmouty-Quintana | Q64856519 |
| P2093 | author name string | Yang Zhou | |
| Keshava Rajagopal | |||
| Andrew J Bryant | |||
| Lavannya M Pandit | |||
| Nancy Wareing | |||
| Sandeep Sahay | |||
| P2860 | cites work | Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis | Q60950058 |
| Pulmonary hypertension in chronic lung disease and hypoxia | Q61810184 | ||
| Haemodynamic definitions and updated clinical classification of pulmonary hypertension | Q61810188 | ||
| Spontaneous pulmonary hypertension in genetic mouse models of natural killer cell deficiency | Q63916390 | ||
| Out-of-proportion pulmonary hypertension: a paradigm for rare diseases | Q64039784 | ||
| Inflammation and immunity in IPF pathogenesis and treatment. | Q64977129 | ||
| Vascular bound recombinant extracellular superoxide dismutase type C protects against the detrimental effects of superoxide radicals on endothelium-dependent arterial relaxation | Q67485921 | ||
| Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial | Q84042517 | ||
| Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction | Q85849107 | ||
| Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design | Q88560048 | ||
| Pharmacology of Adenosine Receptors: The State of the Art | Q88922234 | ||
| Endothelial-derived endothelin-1 promotes pulmonary vascular remodeling in bleomycin-induced pulmonary fibrosis | Q89279368 | ||
| Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis | Q90647238 | ||
| Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence | Q90711506 | ||
| Alterations in cardiovascular function in an experimental model of lung fibrosis and pulmonary hypertension | Q91138188 | ||
| Lung transplantation for idiopathic pulmonary fibrosis | Q91436674 | ||
| Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018 | Q91464763 | ||
| Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema | Q91623088 | ||
| Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease | Q92404817 | ||
| Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension | Q93341312 | ||
| Rho‐kinase/ROCK: A key regulator of the cytoskeleton and cell polarity | Q24298069 | ||
| Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials | Q28237583 | ||
| Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis | Q28240230 | ||
| A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis | Q28240241 | ||
| Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial | Q28290201 | ||
| BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis | Q28308276 | ||
| Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction | Q30412726 | ||
| Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial | Q30430662 | ||
| The Concise Guide to PHARMACOLOGY 2015/16: Overview | Q30488640 | ||
| Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. | Q30600509 | ||
| Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases | Q33677369 | ||
| Transglutaminase regulation of cell function. | Q33707936 | ||
| Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies | Q33849207 | ||
| Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension | Q33898213 | ||
| Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension | Q33909537 | ||
| Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis | Q34223462 | ||
| Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension | Q34415739 | ||
| Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia | Q34480466 | ||
| Herpes virus infection is associated with vascular remodeling and pulmonary hypertension in idiopathic pulmonary fibrosis | Q34611385 | ||
| A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis | Q34619709 | ||
| Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities | Q34773982 | ||
| The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes | Q35115789 | ||
| Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. | Q35185482 | ||
| Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. | Q40195209 | ||
| Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. | Q41635365 | ||
| Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis | Q41770246 | ||
| Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. | Q42173250 | ||
| Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling | Q42734889 | ||
| Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis | Q43220258 | ||
| Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. | Q43292319 | ||
| Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial | Q44158735 | ||
| Perivascular fibrosis of muscular pulmonary arteries in chronic obstructive pulmonary disease | Q45198590 | ||
| Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial | Q45810966 | ||
| Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. | Q46064623 | ||
| Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease | Q46085182 | ||
| Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis | Q46109875 | ||
| Arginase inhibition prevents inflammation and remodeling in a guinea pig model of chronic obstructive pulmonary disease. | Q46210382 | ||
| A randomised, controlled trial of bosentan in severe COPD. | Q46617760 | ||
| Targeting HIF-1α/PDK1 Axis by Dichloroacetate (DCA) Suppresses Bleomycin-induced Pulmonary Fibrosis | Q46792366 | ||
| Dichloroacetate prevents but not reverses the formation of neointimal lesions in a rat model of severe pulmonary arterial hypertension | Q46854074 | ||
| SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung | Q46903300 | ||
| BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis | Q46977247 | ||
| Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease. | Q47252779 | ||
| Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. | Q47410087 | ||
| Emerging Therapeutics in Pulmonary Hypertension | Q47700134 | ||
| Targeted inhibition of Six1 attenuates allergic airway inflammation and remodeling in asthmatic mice | Q47946581 | ||
| Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension | Q47962632 | ||
| Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial | Q48080355 | ||
| Idiopathic pulmonary fibrosis: pathogenesis and management. | Q50326794 | ||
| Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats. | Q51501927 | ||
| The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. | Q52595214 | ||
| Leukotriene B4 mediates macrophage influx and pulmonary hypertension in bleomycin-induced chronic neonatal lung injury. | Q52863516 | ||
| Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. | Q54237894 | ||
| Nintedanib in Severe Pulmonary Arterial Hypertension. | Q54979079 | ||
| Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension. | Q55259961 | ||
| rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling. | Q55343523 | ||
| Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension | Q57148780 | ||
| Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension | Q57824322 | ||
| Pulmonary hypertension in interstitial lung disease | Q58002417 | ||
| Macrophage Immunomodulation: The Gatekeeper for Mesenchymal Stem Cell Derived-Exosomes in Pulmonary Arterial Hypertension? | Q58700113 | ||
| Role of SOD3 in silica-related lung fibrosis and pulmonary vascular remodeling | Q59336693 | ||
| Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. | Q35535817 | ||
| Transglutaminase 2: a molecular Swiss army knife | Q35693361 | ||
| The Role of PPARgamma in pulmonary vascular disease | Q35794254 | ||
| The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation | Q35878712 | ||
| Regulation of smooth muscle calcium sensitivity: KCl as a calcium-sensitizing stimulus | Q36068027 | ||
| Sildenafil improves walk distance in idiopathic pulmonary fibrosis | Q36175304 | ||
| Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis | Q36196758 | ||
| Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension | Q36608217 | ||
| Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots | Q36719113 | ||
| Altered Hypoxic-Adenosine Axis and Metabolism in Group III Pulmonary Hypertension | Q36765972 | ||
| Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension | Q36817403 | ||
| The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease | Q36832901 | ||
| The role of hyaluronan in the pathobiology and treatment of respiratory disease | Q36902371 | ||
| The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance | Q37346515 | ||
| Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis | Q37492223 | ||
| Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways | Q37620501 | ||
| Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. | Q37668859 | ||
| Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. | Q37688525 | ||
| PPARgamma and the pathobiology of pulmonary arterial hypertension | Q37702992 | ||
| Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors | Q37807829 | ||
| World Health Organization Group III pulmonary hypertension | Q38046297 | ||
| HIF-dependent induction of adenosine A2B receptor in hypoxia | Q38308002 | ||
| Angiotensins as therapeutic targets beyond heart disease. | Q38408467 | ||
| Cerebroprotective effects of RAS inhibitors: Beyond their cardio-renal actions. | Q38461657 | ||
| Myeloid-derived Suppressor Cells are Necessary for Development of Pulmonary Hypertension | Q38597953 | ||
| Nintedanib macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis | Q38621547 | ||
| Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis | Q38639439 | ||
| Pulmonary hypertension in parenchymal lung diseases: any future for new therapies? | Q38669161 | ||
| Inhibition of Hyaluronan Synthesis Attenuates Pulmonary Hypertension Associated with Lung Fibrosis. | Q38688645 | ||
| Challenges and opportunities in treating inflammation associated with pulmonary hypertension | Q38812727 | ||
| Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. | Q38988403 | ||
| Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase | Q39198610 | ||
| Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. | Q39665974 | ||
| Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension | Q39673639 | ||
| P921 | main subject | pulmonary hypertension | Q1128595 |
| idiopathic pulmonary fibrosis | Q2290446 | ||
| pulmonary fibrosis | Q32446 | ||
| P577 | publication date | 2020-03-03 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra |
Search more.